# PUBLIC SUMMARY DOCUMENT

**Product:** Hollister Moderma Flex CeraPlus Multi-Chamber Urostomy Flat

**Applicant:** Hollister

**Date of SPAP Meeting:** 22 October 2019

## Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the Hollister Moderma Flex CeraPlus
Multi-Chamber Urostomy Flat in subgroup 3(a) of the Stoma Appliance Scheme (SAS) Schedule. The product was proposed for listing at a unit price of $4.674, with a maximum monthly quantity of 60 units.

## Comparator

The applicant nominated Moderma Flex Urostomy Flat, CTF (Upgraded Design)
(SAS code 80117Q) as the comparator. The product is currently listed in subgroup 3(a) of the SAS Schedule at the unit price of $4.674, with a maximum monthly quantity of 60 units.

## Background

This was the Stoma Product Assessment Panel’s (SPAP) first consideration of this product.

## Clinical Place for the Product

The proposed product is an alternative for users requiring a one-piece urostomy pouch with flat baseplate.

## SPAP Comment

### Clinical Analysis

The Panel noted that the proposed product includes new and enhanced features of the urostomy pouch, which are claimed to be designed to provide comfort and discretion for the user.

The applicant states the proposed product is identical to the comparator product with the addition of the ceramide infused skin barrier.

The Panel agreed that the proposed product is equivalent to products currently available at the benchmark price in subgroup 3(a), therefore listing on a cost minimisation basis was considered appropriate.

### Economic Analysis

Not undertaken.

### Financial Analysis

Listing of this product is recommended on a cost-minimisation basis compared to products currently listed in subgroup 3(a) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

## SPAP Recommendation

The SPAP recommended that the Hollister Moderma Flex CeraPlus Multi-Chamber Urostomy Flat be listed in subgroup 3(a) of the SAS Schedule, at the unit price of $4.674, with a maximum monthly quantity of 60 units.

## Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Hollister agrees with the SPAP’s recommendation.